Clinical Trial Update: RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial [Phase 2]

View source ↗

Summary

This clinical trial update notes termination of the RESPeCT study evaluating lenalidomide (Revlimid) in early-stage poor prognosis chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: The Christie NHS Foundation Trust | Conditions: Chronic Lymphocytic Leukaemia | Phase 2 | Status: TERMINATED